Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

Share Price is delayed by 15 minutes
Get Live Data
2.70    0.05 (1.89%)
Bid:
2.65
Ask:
2.70
Spread: 0.05 (1.887%)
Market Cap: £4.93m
NANO Live PriceLast checked at - London Stock Exchange

Intraday Nanoco Share Chart

Trading Update

16 Aug 2022 07:00

RNS Number : 0970W
Nanoco Group PLC
16 August 2022
 

16 August 2022

 

NANOCO GROUP PLC

("Nanoco", the "Company" or the "Group")

 

Year End Trading Update

 

Notice of Results

 

"Positive organic momentum and extended cash runway ahead of Samsung trial"

 

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other specific nanomaterials emanating from our technology platform, today provides the following year end trading update ahead of the announcement of its final results for the year to 31 July 2022, which will be released in October 2022.

Financial highlights:

· Unaudited revenues of £2.4m for the year ended 31 July 2022, in line with the Board's expectations and just over 10% above FY21.

· Continued proactive management of the cost base resulting in a reduced Adjusted LBITDA, slightly ahead of the Board's expectations.

· Unaudited cash position at 31 July 2022 of £6.8m, an increase of £5.0m since 31 January 2022, reflecting the over-subscribed £5.4m equity raise (net) in June 2022 and good operating cash performance in H2 FY22.

· Cash runway extended to calendar year 2025, beyond the expected point at which the Group's organic operations become self-financing.

 

Operational highlights

· Major work package (the fifth) for European electronics customer signed in June 2022, further underpinning the Group's cash runway.

· Additional development work and material supplies continue for the major Asian chemical company.

· Group order book more than doubled year-on-year.

· Ongoing consolidation of the Group's operations in to one facility in Runcorn.

Litigation update

· As previously announced, trial set to start 12 September 2022 and expected to last one week.

· Pre-trial conference date has been set for 18-19 August 2022.

· Judge issued ruling rejecting Samsung motion to change the definitions of an important technical term in the case (previously decided in Nanoco's favour at the Markman hearing).

Final results date

The Company expects to announce its final results for the year ended 31 July 2022 in the second half of October 2022.

 

 

Brian Tenner, Chief Executive of Nanoco, said:

"The Group delivered two very important milestones in the second half of FY22. We emphatically won all five patents and all 47 claims that were contested by Samsung at the Patent Trial and Appeal Board. We also delivered a significant contract extension with our European electronics customer that covers the work required to scale up and validate our nano-materials for production readiness.

 

"We move forward with confidence to the scheduled trial in the IP litigation on 12 September 2022 and to validating our products in H1 of FY23, ahead of expected visibility of production orders shortly thereafter. We are completing the relocation of our Manchester operations into the consolidated site in Runcorn to deliver operational benefits and real cash savings.

 

"The combination of strong progress on the IP litigation and the underlying organic business is a robust platform to deliver significant value to all of our stakeholders in the short to medium term."

 

- Ends -

For further information, please contact:

Nanoco Group PLC:

Brian Tenner, CEO +44 (0) 161 603 7900

Liam Gray, CFO & Company Secretary +44 (0) 161 603 7900

 

Peel Hunt (Joint Corporate Broker):

Edward Knight +44 (0) 20 7418 8900

James Smith

 

Turner Pope Investments (Joint Corporate Broker):

Andrew Thacker +44 (0) 20 3657 0050

James Pope

 

MHP Communications: +44 (0) 203 128 8570

Reg Hoare

Pete Lambie

nanoco@mhpc.com

 

Notes for editors:

About Nanoco Group plc

Nanoco (LSE: NANO) harnesses the power of nano-materials. Nano-materials are materials with dimensions typically in the range 1 - 100 nm. Nano-materials have a range of useful properties, including optical and electronic. Quantum dots are a subclass of nano-material that have size-dependent optical and electronic properties. The Group produces quantum dots and other nano-materials. Within the sphere of quantum dots, the Group exploits different characteristics of the quantum dots to target different performance criteria that are attractive to specific markets or end-user applications such as the Display, Sensor and Electronics markets. An interesting property of quantum dots is their absorption spectrum. Nanoco's HEATWAVE™ quantum dots can be tuned to absorb light at different wavelengths across the near-infrared spectrum, rendering them useful for applications including image sensors. Another interesting property of quantum dots is photoluminescence: the emission of longer wavelength light upon excitation by light of a shorter wavelength. The colour of light emitted depends on the particle size. Nanoco's CFQD® quantum dots are free of cadmium and other toxic heavy metals, and can be tuned to emit light at different wavelengths across the visible and infrared spectrum, rendering them useful for a wide range of applications including displays, lighting and biological imaging.

Nanoco was founded in 2001 and is headquartered in Manchester, UK, with a US subsidiary, Nanoco Inc., in Concord, MA. Nanoco continues to build out a world-class, patent-protected IP portfolio generated both by its own innovation engine, as well as through acquisition.

Nanoco is listed on the Main Market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocotechnologies.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPAMBTMTJBTBT
Date   Source Headline
20th Dec 20227:00 amRNSAGM Statement
13th Dec 20227:00 amRNSBlock listing Six-monthly Return
9th Dec 20227:00 amRNSLitigation Update - Firm Trial Date
14th Nov 202210:46 amRNS2022 Annual Report and Notice of AGM
7th Nov 20224:13 pmRNSHolding(s) in Company
27th Oct 20225:19 pmRNSDirector/PDMR Shareholding
26th Oct 20222:31 pmRNSLitigation Update – Funded Law Suit Filed in China
20th Oct 20227:00 amRNSPreliminary Results
14th Oct 202212:59 pmRNSPresentation via Investor Meet Company
14th Oct 202210:41 amRNSNotice of Results
28th Sep 20227:00 amRNSLitigation Update – Further Revised Trial Date
12th Sep 20228:25 amRNSTrading Update & Directorate Change
7th Sep 20223:47 pmRNSLitigation Update – Revised Trial Date
1st Sep 202210:22 amRNSDirector/PDMR Shareholding
31st Aug 20227:00 amRNSTwo Grant Funding Awards
30th Aug 20223:33 pmRNSHolding(s) in Company
30th Aug 20223:28 pmRNSDirector/PDMR Shareholding
25th Aug 20221:36 pmRNSDirector/PDMR Shareholding
23rd Aug 20222:22 pmRNSFunded Law Suit Filed in Germany
19th Aug 20228:21 amRNSLitigation Update – Pre-Trial Conference
18th Aug 20224:10 pmRNSDirector/PDMR Shareholding
16th Aug 20227:00 amRNSTrading Update
28th Jul 202210:42 amRNSHolding(s) in Company
13th Jul 20222:03 pmRNSReplacement - Director/PDMR Shareholding
13th Jul 202212:00 pmRNSHolding(s) in Company
13th Jul 202212:00 pmRNSDirector/PDMR Shareholding
13th Jul 202212:00 pmRNSHolding(s) in Company
30th Jun 20227:00 amRNSTotal Voting Rights
29th Jun 20227:00 amRNSChange of Auditor
23rd Jun 20223:48 pmRNSDirector/PDMR Shareholding
22nd Jun 20222:25 pmRNSHolding(s) in Company
21st Jun 20223:36 pmRNSDirector/PDMR Shareholding
21st Jun 20229:06 amRNSReplacement: Director/PDMR Shareholding
21st Jun 20227:00 amRNSDirector/PDMR Shareholding
17th Jun 20224:36 pmRNSPrice Monitoring Extension
17th Jun 202210:45 amRNSHolding(s) in Company
14th Jun 20229:42 amRNSHolding(s) in Company
9th Jun 20227:00 amRNSBlock listing Six-monthly Return
8th Jun 202212:00 pmRNSResults of Fundraise
8th Jun 20227:00 amRNSFundraise significantly over-subscribed
7th Jun 20225:16 pmRNSReplacement: Litigation Update
7th Jun 20224:55 pmRNSLitigation Update
6th Jun 20227:02 amRNSTrading Update & Proposed Fundraise
6th Jun 20227:00 amRNSMajor Work Package for European Customer
23rd May 20225:00 pmRNSHolding(s) in Company
17th May 20227:02 amRNSLitigation Update
13th May 202212:15 pmRNSHolding(s) in Company
13th Apr 20222:49 pmRNSHolding(s) in Company
12th Apr 20227:00 amRNSInterim Results
17th Mar 20227:00 amRNSAdditional Work Package for European Customer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.